Epidemiologic variables are compared across PH risk tertiles and binary PH risk status, respectively
| Cohort demographic data . | |||||||
|---|---|---|---|---|---|---|---|
| . | PH risk tertile . | PH risk binary . | |||||
| Normal . | Mild PH risk . | High PH risk . | P value† . | Normal . | Increased PH risk . | P value‡ . | |
| n = 110∗ . | N = 16∗ . | N = 8∗ . | N = 110∗ . | N = 24∗ . | |||
| Sex | .7 | .7 | |||||
| Female | 57 (52%) | 10 (63%) | 4 (50%) | 57 (52%) | 14 (58%) | ||
| Male | 53 (48%) | 6 (38%) | 4 (50%) | 53 (48%) | 10 (42%) | ||
| Age | 70 (59-79) | 78 (74-82) | 79 (72-85) | .009 | 70 (59-79) | 78 (74-83) | <.001 |
| Death during study period | 31 (28%) | 10 (63%) | 6 (75%) | .001 | 31 (28%) | 16 (67%) | <.001 |
| CV death | 4 (15%) | 3 (43%) | 3 (60%) | .039 | 4 (15%) | 6 (50%) | .043 |
| Duration of PV diagnosis | 3 (1-9) | 13 (9-19) | 8 (2-10) | <.001 | 3 (1-9) | 11 (5-17) | .002 |
| No. of ECHOs performed | 1.00 (1.00- 3.00) | 1.50 (1.00- 3.50) | 2.00 (2.00- 4.00) | .8 | 1.00 (1.00- 3.00) | 2.00 (1.00- 4.00) | .5 |
| RHC Performed | 10 (9.1%) | 2 (13%) | 4 (50%) | .003 | 10 (9.1%) | 6 (25%) | .067 |
| ECHO parameters | |||||||
| TR jet velocity | 2.42 (2.19- 2.61) | 2.99 (2.92- 3.04) | 3.68 (3.54- 3.84) | <.001 | 2.42 (2.19- 2.61) | 3.04 (2.95- 3.54) | <.001 |
| TAPSE | 2.20 (1.93- 2.52) | 2.24 (2.00- 2.60) | 1.73 (1.50- 2.69) | .4 | 2.20 (1.93- 2.52) | 2.00 (1.70- 2.69) | .5 |
| LVEF | 66 (60-68) | 63 (43-65) | 60 (56-66) | .026 | 66 (60-68) | 63 (46-65) | .052 |
| LA diameter (cm) | 3.61 (3.40- 4.07) | 3.40 (2.80- 3.90) | 5.10 (4.13- 6.10) | <.001 | 3.61 (3.40- 4.07) | 4.01 (3.30- 5.55) | .3 |
| E:E′ | 10.8 (8.3-13.2) | 13.4 (10.4- 14.9) | 18.1 (15.7- 30.7) | <.001 | 10.8 (8.3- 13.2) | 14.1 (12.5- 16.5) | .031 |
| LA volume | 18 (15-23) | 23 (16-27) | 33 (22-36) | <.001 | 18 (15-23) | 27 (17-33) | .012 |
| RV diameter (cm) | 3.57 (3.22- 3.92) | 3.58 (3.57- 4.28) | 4.85 (4.55- 5.25) | .02 | 3.57 (3.22- 3.92) | 4.42 (3.58- 5.05) | .3 |
| History of thrombosis | 36 (33%) | 8 (50%) | 5 (63%) | .12 | 36 (33%) | 13 (54%) | .082 |
| JAK2+ | 107 (99%) | 14 (100%) | 6 (100%) | >.9 | 107 (99%) | 20 (100%) | >.9 |
| Transformed to MF | 4 (3.6%) | 4 (25%) | 1 (13%) | .005 | 4 (3.6%) | 5 (21%) | .009 |
| BMI | 25.0 (22.2- 28.1) | 24.6 (21.5- 26.9) | 21.0 (20.3- 27.9) | .3 | 25.0 (22.2- 28.1) | 24.3 (20.5- 27.0) | .12 |
| Antiplatelet agents and anticoagulants | |||||||
| Aspirin | 83 (75%) | 11 (69%) | 6 (75%) | .8 | 83 (75%) | 17 (71%) | .8 |
| Full-dose anticoagulation | 18 (16%) | 2 (13%) | 3 (38%) | .3 | 18 (16%) | 5 (21%) | .8 |
| Cytoreductive agents | |||||||
| Hydroxyurea | 43 (39%) | 9 (56%) | 4 (50%) | .4 | 43 (39%) | 13 (54%) | .3 |
| Ruxolitinib | 13 (12%) | 3 (19%) | 2 (25%) | .5 | 13 (12%) | 5 (21%) | .4 |
| Anagrelide | 1 (0.9%) | 3 (19%) | 1 (13%) | <.001 | 1 (0.9%) | 4 (17%) | .002 |
| Peginterferon | 26 (24%) | 0 (0%) | 0 (0%) | .03 | 26 (24%) | 0 (0%) | .018 |
| NYHA FC | .4 | .4 | |||||
| 1-2 | 10 (71%) | 1 (33%) | 2 (50%) | 10 (71%) | 3 (43%) | ||
| 3-4 | 4 (29%) | 2 (67%) | 2 (50%) | 4 (29%) | 4 (57%) | ||
| Comorbidities | |||||||
| HTN | 62 (56%) | 9 (56%) | 6 (75%) | .6 | 62 (56%) | 15 (63%) | .7 |
| DM | 15 (14%) | 3 (19%) | 1 (13%) | .9 | 15 (14%) | 4 (17%) | >.9 |
| HLD | 51 (46%) | 8 (50%) | 4 (50%) | >.9 | 51 (46%) | 12 (50%) | >.9 |
| CAD | 22 (20%) | 1 (6.3%) | 3 (38%) | .2 | 22 (20%) | 4 (17%) | >.9 |
| OSA | 11 (10%) | 0 (0%) | 2 (25%) | .14 | 11 (10%) | 2 (8.3%) | >.9 |
| WBC | 9 (6-17) | 8 (6-25) | 20 (12-28) | >.9 | 9 (6-17) | 15 (6-28) | .7 |
| Hematocrit | 41 (33-47) | 36 (28-41) | 37 (34-41) | .5 | 41 (33-47) | 36 (32-41) | .078 |
| Platelet Count | 289 (132-441) | 489 (256- 756) | 410 (210- 561) | .012 | 289 (132- 441) | 479 (250- 701) | .019 |
| LDH | 237 (198-329) | 329 (216- 413) | 352 (205- 487) | >.9 | 237 (198- 329) | 330 (207- 443) | .6 |
| BNP | 114 (67-367) | 180 (132- 316) | 227 (170- 1,213) | .2 | 114 (67- 367) | 204 (140- 765) | .2 |
| Cohort demographic data . | |||||||
|---|---|---|---|---|---|---|---|
| . | PH risk tertile . | PH risk binary . | |||||
| Normal . | Mild PH risk . | High PH risk . | P value† . | Normal . | Increased PH risk . | P value‡ . | |
| n = 110∗ . | N = 16∗ . | N = 8∗ . | N = 110∗ . | N = 24∗ . | |||
| Sex | .7 | .7 | |||||
| Female | 57 (52%) | 10 (63%) | 4 (50%) | 57 (52%) | 14 (58%) | ||
| Male | 53 (48%) | 6 (38%) | 4 (50%) | 53 (48%) | 10 (42%) | ||
| Age | 70 (59-79) | 78 (74-82) | 79 (72-85) | .009 | 70 (59-79) | 78 (74-83) | <.001 |
| Death during study period | 31 (28%) | 10 (63%) | 6 (75%) | .001 | 31 (28%) | 16 (67%) | <.001 |
| CV death | 4 (15%) | 3 (43%) | 3 (60%) | .039 | 4 (15%) | 6 (50%) | .043 |
| Duration of PV diagnosis | 3 (1-9) | 13 (9-19) | 8 (2-10) | <.001 | 3 (1-9) | 11 (5-17) | .002 |
| No. of ECHOs performed | 1.00 (1.00- 3.00) | 1.50 (1.00- 3.50) | 2.00 (2.00- 4.00) | .8 | 1.00 (1.00- 3.00) | 2.00 (1.00- 4.00) | .5 |
| RHC Performed | 10 (9.1%) | 2 (13%) | 4 (50%) | .003 | 10 (9.1%) | 6 (25%) | .067 |
| ECHO parameters | |||||||
| TR jet velocity | 2.42 (2.19- 2.61) | 2.99 (2.92- 3.04) | 3.68 (3.54- 3.84) | <.001 | 2.42 (2.19- 2.61) | 3.04 (2.95- 3.54) | <.001 |
| TAPSE | 2.20 (1.93- 2.52) | 2.24 (2.00- 2.60) | 1.73 (1.50- 2.69) | .4 | 2.20 (1.93- 2.52) | 2.00 (1.70- 2.69) | .5 |
| LVEF | 66 (60-68) | 63 (43-65) | 60 (56-66) | .026 | 66 (60-68) | 63 (46-65) | .052 |
| LA diameter (cm) | 3.61 (3.40- 4.07) | 3.40 (2.80- 3.90) | 5.10 (4.13- 6.10) | <.001 | 3.61 (3.40- 4.07) | 4.01 (3.30- 5.55) | .3 |
| E:E′ | 10.8 (8.3-13.2) | 13.4 (10.4- 14.9) | 18.1 (15.7- 30.7) | <.001 | 10.8 (8.3- 13.2) | 14.1 (12.5- 16.5) | .031 |
| LA volume | 18 (15-23) | 23 (16-27) | 33 (22-36) | <.001 | 18 (15-23) | 27 (17-33) | .012 |
| RV diameter (cm) | 3.57 (3.22- 3.92) | 3.58 (3.57- 4.28) | 4.85 (4.55- 5.25) | .02 | 3.57 (3.22- 3.92) | 4.42 (3.58- 5.05) | .3 |
| History of thrombosis | 36 (33%) | 8 (50%) | 5 (63%) | .12 | 36 (33%) | 13 (54%) | .082 |
| JAK2+ | 107 (99%) | 14 (100%) | 6 (100%) | >.9 | 107 (99%) | 20 (100%) | >.9 |
| Transformed to MF | 4 (3.6%) | 4 (25%) | 1 (13%) | .005 | 4 (3.6%) | 5 (21%) | .009 |
| BMI | 25.0 (22.2- 28.1) | 24.6 (21.5- 26.9) | 21.0 (20.3- 27.9) | .3 | 25.0 (22.2- 28.1) | 24.3 (20.5- 27.0) | .12 |
| Antiplatelet agents and anticoagulants | |||||||
| Aspirin | 83 (75%) | 11 (69%) | 6 (75%) | .8 | 83 (75%) | 17 (71%) | .8 |
| Full-dose anticoagulation | 18 (16%) | 2 (13%) | 3 (38%) | .3 | 18 (16%) | 5 (21%) | .8 |
| Cytoreductive agents | |||||||
| Hydroxyurea | 43 (39%) | 9 (56%) | 4 (50%) | .4 | 43 (39%) | 13 (54%) | .3 |
| Ruxolitinib | 13 (12%) | 3 (19%) | 2 (25%) | .5 | 13 (12%) | 5 (21%) | .4 |
| Anagrelide | 1 (0.9%) | 3 (19%) | 1 (13%) | <.001 | 1 (0.9%) | 4 (17%) | .002 |
| Peginterferon | 26 (24%) | 0 (0%) | 0 (0%) | .03 | 26 (24%) | 0 (0%) | .018 |
| NYHA FC | .4 | .4 | |||||
| 1-2 | 10 (71%) | 1 (33%) | 2 (50%) | 10 (71%) | 3 (43%) | ||
| 3-4 | 4 (29%) | 2 (67%) | 2 (50%) | 4 (29%) | 4 (57%) | ||
| Comorbidities | |||||||
| HTN | 62 (56%) | 9 (56%) | 6 (75%) | .6 | 62 (56%) | 15 (63%) | .7 |
| DM | 15 (14%) | 3 (19%) | 1 (13%) | .9 | 15 (14%) | 4 (17%) | >.9 |
| HLD | 51 (46%) | 8 (50%) | 4 (50%) | >.9 | 51 (46%) | 12 (50%) | >.9 |
| CAD | 22 (20%) | 1 (6.3%) | 3 (38%) | .2 | 22 (20%) | 4 (17%) | >.9 |
| OSA | 11 (10%) | 0 (0%) | 2 (25%) | .14 | 11 (10%) | 2 (8.3%) | >.9 |
| WBC | 9 (6-17) | 8 (6-25) | 20 (12-28) | >.9 | 9 (6-17) | 15 (6-28) | .7 |
| Hematocrit | 41 (33-47) | 36 (28-41) | 37 (34-41) | .5 | 41 (33-47) | 36 (32-41) | .078 |
| Platelet Count | 289 (132-441) | 489 (256- 756) | 410 (210- 561) | .012 | 289 (132- 441) | 479 (250- 701) | .019 |
| LDH | 237 (198-329) | 329 (216- 413) | 352 (205- 487) | >.9 | 237 (198- 329) | 330 (207- 443) | .6 |
| BNP | 114 (67-367) | 180 (132- 316) | 227 (170- 1,213) | .2 | 114 (67- 367) | 204 (140- 765) | .2 |
BMI, body mass index; BNP, brain natriuretic preptide; CAD, coronary artery disease; CV, cardiovascular; DM, diabetes mellitus; E:E′, ratio between early mitral inflow velocity and mitral annular early diastolic velocity; HTN, hypertension; LVEF, left ventr; LA,left atrium; LDH, lactate dehydrogenase; NYHA FC, New York Heart Associate functional classification; OSA, obstructive sleep apnea; WBC, white blood cells.
n (%); median (Q1-Q3).
Pearson χ2 test; 1-way analysis of means; Fisher exact test.
Pearson χ2 test; Welch 2-sample t test; Fisher exact test.